Drug
Liposomal Mitoxantrone
Liposomal Mitoxantrone is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(33%)
Phase Distribution
Ph not_applicable
1
33%
Ph phase_2
2
67%
Phase Distribution
0
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Other(1)
Detailed Status
unknown1
Not yet recruiting1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 22 (66.7%)
N/A1 (33.3%)
Trials by Status
unknown133%
not_yet_recruiting133%
recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
not_yet_recruitingnot_applicable
Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML
NCT07490288
recruitingphase_2
Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma
NCT05958719
unknownphase_2
Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients
NCT05823701
Clinical Trials (3)
Showing 3 of 3 trials
NCT07490288Not Applicable
Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML
NCT05958719Phase 2
Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma
NCT05823701Phase 2
Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3